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Background: Diabetes mellitus (DM) is an incurable metabolic disease constituting a major threat to human health.
Insulin-producing cells (IPCs) differentiated from mesenchymal stem cells (MSCs) hold great promise in the treatment
of DM. The development of an efficient IPC induction system is a crucial step for the clinical application of IPCs for DM.
Laminin 411 is a key component of the basement membrane and is involved in the regulation of cell differentiation;
however, little is known about a role of laminin 411 in the regulation of IPC differentiation from human MSCs.
Methods: MSCs were isolated from human umbilical cord (UC-MSCs) and expanded in an in vitro culture system.
UC-MSCs were then cultured in the IPC induction and differentiation medium in the presence of laminin 411. Flow
cytometry, Quantitative realtime PCR, immunofluorescence staining, ELISA, Western blotting and other techniques were
applied to determine IPC generation, insulin expression and related mechanisms. To evaluate potential therapeutic
efficacy of IPCs induced from UC-MSCs, a type-1 diabetes (T1DM) rat model was generated using streptozotocin. Blood
glucose, insulin levels, and survival of rats were monitored periodically following intravenous injection of the tested cells.
Results: Laminin 411 markedly induced the expression of the genes Foxa2 and Sox17, markers for pancreatic precursor
cells, efficiently induced IPC differentiation from MSCs, and up-regulated insulin expression at both mRNA and
protein levels. Furthermore, the expression of the genes known to govern insulin expression including Pdx1 and
Ngn3 was markedly induced by laminin 411, which suggests that Pdx1 and Ngn3 signaling pathways are involved
in laminin 411 induced-insulin expression machinery. More importantly, administration of laminin 411-induced
IPCs rapidly and significantly down-regulated fasting blood glucose levels, significantly reduced the HbA1c
concentration and markedly improved the symptoms and survival of T1DM rats.
Conclusions: Our results demonstrate that laminin 411 acts as a potent differentiation inducer of IPCs from
UC-MSCs via the Pdx1 and Ngn3 signaling pathways. Moreover, transfusion of laminin 411 induced-IPCs more
efficiently improves symptoms and survival of T1DM rats. These novel finding highlights a potential clinical application
of laminin 411 induced-IPCs in the treatment of T1DM, which calls for further studies.
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Diabetes mellitus (DM) is a group of metabolic disorders
of carbohydrate metabolism, which constitutes a major
threat to human health worldwide, particularly in in-
dustrialized countries. The main feature of the disease
is hyperglycemia resulting from overproduction and
underutilization of glucose [1]. DM is briefly classified
into two subtypes, type-1 (T1DM) and type-2 (T2DM).
Classical treatments of DM consist of insulin injection
and orally taking hypoglycemic drugs. Such daily the-
rapeutic approaches markedly affect life quality of DM
patients due to side-effects of the hypoglycemic drugs
and suffering of injection. Thus, novel treatments with
long-lasting efficacy and lower side-effects are urgently
needed. Studies on islet transplantation for DM have
shown promising results [2,3], but the long-term efficacy
is still unsatisfying. In addition, shortage of donors for
islets and poor in vitro expansion capacity of islets
remain unresolved, which limit the use of such therapy
in the clinical setting. Therefore, developing alternative
cellular therapy strategies for DM is an urgent task.
Mesenchymal stem cells (MSCs) have gained interest
because of its potential application in regeneration medi-
cine and cytotherapy. MSCs are a kind of pluripotent
adult stem cells with the advantage of lower immuno-
genicity and the ability toward osteogenesis, adipogene-
sis, and chondrogenesis differentiation [4]. MSCs can be
obtained from numerous sources, such as bone marrow
(BM), umbilical cord tissue, adipose tissue, dental pulp,
amniotic fluid, and pancreatic islets [5]. Previous studies
demonstrated that intravenous infusion of MSCs de-
creased blood glucose level in Balb/c diabetes mice [6],
and prevented autoimmune diabetes in NOD mice [7].
In contrast to the results obtained from the above
animal studies, our polite clinical trial using intravenous
transfusion of human umbilical cord Wharton’s jelly
derived MSCs (UC-MSC) did not yield satisfying results
(unpublished data).
Tang et al. reported that BM-derived stem cells de-
rived from Balb/c mice could be trans-differentiated into
insulin-producing cells (IPCs), but this process requires
more than 2 months to generate the insulin-producing
cluster [8]. In 2007, Karnieli et al described for the first
time a protocol for human BM-derived MSCs differen-
tiated into IPCs by gene manipulation [9]. Since then,
various protocols for IPC differentiation have been pub-
lished. Briefly these protocols can be divided into 2 types:
one is to apply gene manipulation techniques (e.g. Pdx1
transfection) [10], and another is to use small molecules
and/or growth factors to induce IPC differentiation.
Conceivably, gene manipulation requires the technique
transfecting target cells using a viral vector encoding
specific genes. For the concern of bio-safety, the cells hav-
ing undergone gene manipulation are not very promisingfor clinical use. Non-gene manipulation protocols for
IPC differentiation has been described, however, their
induction efficiency of IPC differentiation from stem
cells remains poor, only 10-20% differentiation rate [11].
Thus, it is urgently demanding a highly efficient proto-
col for IPC generation.
Laminin is a heterotrimer glycoprotein that contains
alpha, beta, and gamma chains. To date, at least 19 laminin
isoforms have been identified [12], and it is named
according to its sub-chain types, e.g., laminin 411 com-
prises the α4, β1, and γ1 chains [13]. Laminin is a key
component of the basement membrane, and is involved
in the structural scaffold, cell proliferation, and diffe-
rentiation. Previous studies showed that laminin 111 pro-
moted the differentiation of fetal mouse pancreatic beta
cells [14], and induced the expression of islet cell markers
in the hepatic oval cells in vitro [15]. Moreover, Laminin
was observed to promote differentiation of the hTERT-
over-expressed human BM derived-MSCs into IPCs [16].
In this study, we tested potential activity of laminin
411 on induction of human UC-MSC into IPCs with-
out any gene manipulation and therapeutic effects of the
IPCs on DM animal models. Our results demonstrated
that the laminin 411-based protocol significantly enhanced
the induction of IPC differentiation from UC-MSC, and
these IPCs produced significantly higher levels of insulin
than those without laminin 411. Moreover, the animal
study showed that intravenous administration of laminin
411-induced IPCs (IPC + 411) rapidly reduced fasting
blood glucose (FBG) levels, significantly prolonged the
survival and improved DM signs when compared to
untreated controls.
Materials and methods
UC-MSC culture and expansion
Human umbilical cord (UC) specimens were collected
from the obstetrical department of the Second Hospital
of Shandong University. Ethic committee of Second
Hospital of Shandong University approved the study and
informed consents were obtained from all donors. UC
tissue we rinsed with phosphate-buffered saline (PBS).
Wharton’s jelly tissue was chopped into small pieces
and digested with collagenase and trypsin (Gibco BRL,
Gaithersburg, MD, USA). Finally, UC-MSCs were cul-
tured in DMEM complete medium (Thermo, Logan,
UT, USA), containing 10% defined fetal bovine serum
(Biowest, NuaillÃ, France), L-glutamine (2 mM; Life
Technologies, Carlsbad, CA, USA), growth factors
(R&D Systems, Lille, France), penicillin and strepto-
mycin (Life Technologies). Cells were cultured in a
humidified atmosphere with 5% CO2 at 37°C. After
72 hrs of incubation, non-adherent cells were carefully
removed and fresh medium were added. When the cell
density reached 80% confluence, they were passaged.
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The uniform spindle-fibroblastic morphology and adher-
ent phenotype was identified under an inverted micro-
scope (Nikon Corp., Tokyo, Japan). UC-MSCs were
resuspended in PBS, stained with fluorescence-labeled
monoclonal antibodies CD34, HLA-DR, CD105, CD73,
CD90, and CD45 (BD, Franklin Lakes, NY, USA), and then
incubated for 30 min at 4°C in the dark. Appropriate iso-
type controls were included (for each antibody isotype).
The expression of the above cell surface markers was eval-
uated using LSRFortessa Flow Cytometer (BD).UC-MSC differentiation assays
Differentiation kits (Life Technologies) were used ac-
cording to the manufacturer’s instructions. Briefly,
UC-MSCs were seeded at 1 × 104/cm2, and incubated
in the adipose and osteoblast differentiation culture
media for 21 d, respectively. Adipocytes and osteocytes
were stained with oil red O and Alzarin red, respect-
ively. For chondrogenesis differentiation, UC-MSCs
were placed in a DMEM complete culture media at
1.6 × 107 cells/ml. UC-MSCs were seeded with 5 μl
droplets placed in chondrogenesis culture media for 14 d.
The micromass cultures were then stained with Alcian
blue.IPC differentiation protocol
UC-MSCs from passage 4 were used for IPC differenti-
ation (Figure 1). Undifferentiated cells were suspended
in complete culture media and aliquots of 2.5 × 105 cells,
and placed in 6-well plates overnight. The medium was re-
placed with complete culture media either with or without
pre-coated 5 μg/mL laminin 411 (Biolamina, Stockholm,
Sweden) and 25 mM glucose for 3 d (stage I). At stage II,
the media were refreshed with DMEM/F-12 medium
containing Insulin-Transferin-Selenium-A (ITS-A, BD) for
another 4 d. At stage III, 10 mM nicotinamide (MP, USA)
was added into the media, and the culture lasted for 3 days.
At stage IV, the medium was changed with the same sup-
plements as at stage III, but N2 and B27 supplements
(Invitrogen) were added and incubated for 4 d.Figure 1 Illustrations of the IPC differentiation protocol. Undifferentiat
2.5 × 105 cells and placed in 6-well plates overnight. The medium was repl
pre-coated 5 μg/mL laminin 411 and 25 mM glucose for 3 d (stage I). At st
Insulin-Transferin-Selenium-A for another 4 d. At stage III, 10 mM nicotinam
the medium was changed with the same supplements at stage III, but N2Dithizone (DTZ) staining
DTZ (Sigma-Aldrich, St. Louis, MO, USA) stock solu-
tion was prepared by dissolving 100 mg of DTZ in 5 ml
DMSO. The induced cells were added into 1 mL 1× PBS
buffer and 10 μL DTZ stock solution, and then incu-
bated at 37°C for 15 min. The crimson red stained clus-
ters were examined under a phase-contrast microscope
(Nikon Corp.).
Immunofluorescence
Cultured cells and clusters were fixed, permeabilized in
PBS +0.1% Triton X-100, and then blocked for 30 min
in PBS +0.5% Tween-20 (PBST) containing 1% BSA.
Cells were incubated with insulin and Pdx1 primary
antibodies, followed by the incubation with the second-
ary antibodies. Cell nuclei were stained with DAPI (Life
Technologies). Images were acquired with fluorescence
microscope (Nikon Corp.). The mean fluorescence dens-
ity of the Pdx1 positive staining area was quantified by
ImageJ software (NIH, USA).
Quantitative real time PCR (qPCR)
Total RNA was extracted using Trizol reagent (Life
Technologies) following the manufacturer’s instructions.
Up to 5 μg total RNA were subjected to reverse tran-
scription into cDNA with M-MLV enzyme (Life Tech-
nologies) at 37°C for 50 mins in the presence of an
oligo-dT primer. qPCR was performed using Master
cycler Realplex 2 (Eppendorf, Hauppauge, NY, USA).
The primer sequences were listed in Table 1. The quan-
tification of target gene expression was calculated using
Eppendorf realplex software (Eppendorf ).
Western blot
Cell lysates were extracted using protein extraction re-
agent RIPA buffer containing Triton-x-100 (Sigma-
Aldrich) and a protease inhibitor cocktail (Roche Applied
Sience, Indinapolis, IN, USA). Samples were loaded onto a
10% SDS-polyacrylamide gel. Proteins were transferred
onto PVDF membrane (Millipore, Billerica, USA) with
Trans-Blot® SD Semi-Dry Electrophoretic Transfer Cell
(Biorad, Marnes-La-Coquette, France). The membraneed cells were suspended in complete culture media and aliquots of
aced with complete culture media either with (control) or without
age II, the media were refreshed with DMEM/F-12 medium containing
ide was added to the media, and culture lasted for 3 days. At stage IV,
and B27 supplements were added and incubated for 4 d.
Table 1 Nucleotide sequence of the primers used in this
study
Gene Sequence (5′-3′)
1 Pdx1 F GGAGCCGGAGGAGAACAAG
Pdx1 R CTCGGTCAAGTTCAACATGACAG
2 Pax4 F CAGCGCTGCTGGACTT
Pax4 R CAGCGCTGCTGGACTT
3 Insulin F ACCAGCATCTGCTCCCTCTA
Insulin R GGTTCAAGGGCTTTATTCCA
4 Ngn3 F CTATTCTTTTGCGCCGGTAGA
Ngn3 R CTCACGGGTCACTTGGACAGT
5 Glucagon F CCCAAGATTTTGTGCAGTGGTT
Glucagon R CAGCATGTCTCTCAAATTCATCGT
6 Foxa2 F CTGAGCGAGATCTACCAGTGGA
Foxa2 R CAGTCGTTGAAGGAGAGCGAGT
7 Sox17 F GCATGACTCCGGTGTGAATCT
Sox17 R TCACACGTCAGGATAGTTGCAGT
8 GAPDH F GCACCGTCAAGGCTGAGAAC
GAPDH R TGGTGAAGACGCCAGTGGA
F: forward primer; R: reverse primer.
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Pdx1 (Cell Signaling Technology, Beverly, MA), Ngn3
(Cell Signaling Technology), and GAPDH (Cell Signaling
Technology). After washing, the membrane was incubated
with horseradish peroxidase-conjugated goat anti-rabbit
IgG (Santa Cruz, Dallas, Texas, USA) or anti-mouse IgG
(Santa Cruz). The membrane was washed and developed
using a chemiluminescent HRP substrate (Millipore).
Several exposure times were tested for both ECL with
X-ray film and ECL with CCD imager.
Insulin release assay
IPCs at stage IV from each of the groups described above
were gently washed twice with PBS. The cells were then
pre-incubated in KRB culture media containing glu-
cose (25 mM) at 37°C for 2 hrs and supernatants were
then collected for insulin quantification. An ELISA kit
(Alpco, Salem, USA) was used to assess insulin con-
centration according to manufacturer’s instructions.
Insulin levels were calculated according to the stand-
ard curve.
Animals
Wistar rats (male, 6 to 8 weeks old) were purchased
from the Experimental Animal Centre of Shandong
University. Rats were housed in sterile cages under
laminar flow hoods in a temperature-controlled room with
a 12 h light/dark schedule, and fed with autoclaved chow
and water. The experimental protocol and design of the
study were in accordance with the institutional guidelinesfor animal experiments and approved by the institu-
tional Animal Ethics Research committee of the Second
Hospital of Shandong University.
Cell transfusion in rats
Rats were made hyperglycemic by a single i.p. injection
of 60 mg streptozotocin (STZ; Sigma–Aldrich) per kg of
body weight after fasting [8]. There were 4 rats in each
group tested, and the cells were injected through a tail
vein. When blood glucose reached levels over 16.7 mol/l
within 3 to 7 d of STZ injection, the cells (UC-MSCs,
IPCs with or without exposure to laminin 411 and nor-
mal saline groups) were transfused via tail veins. Fast
blood glucose (FBG) levels were monitored twice a week
using Blood Glucose Test Strips (Roche Diagnostics,
Basel, Switzerland) and HbA1c levels were quantified
using liquid chromatography analyser (Tosoh Europe,
Tessenderlo, Belgium).
Statistical analysis
The Student’s t test and one way ANOVA was applied
to compare differences between the groups. Data were
shown as mean ± SEM. Pearson’s correlation coefficient
was used to test for significance in linear relationships
between variables. SPSS 20.0 software was used for stat-
istical analysis. P < 0.05 was considered as statistical
significance.
Results
UC-MSC culture and expansion
UC-MSCs were spindle shaped and adhered to the plas-
tic flask. The phenotype of UC-MSCs was in accordance
with the International Society for Cellular Therapy 2006
minimal criteria. UC-MSCs were positive for CD73 (99%),
CD90 (99%), CD105 (95%), CD166 (98%), and negative
for hematopoietic marker CD34 (1.7%), monocyte marker
CD14 (1.5%), leukocyte common antigen CD45 (2.2%),
and HLA-DR (1.3%) (Figure 2). To demonstrate dif-
ferentiation pluripotency, UC-MSCs were subjected to
conditions known to induce differentiation into bone,
cartilage, and adipose cells. UC-MSCs were induced
into adipocyte, osteocyte, and chondrocyte in vitro by oil
red O, Alizarin, and Alcian blue, respectively (Figure 3).
In vitro IPC differentiation
We first evaluated UC-MSCs to IPCs differentiation
(Figure 4A) in a 4 stage protocol according to previously
published protocols with modifications [17,18]. UC-MSCs
aggregated together during the differentiation at stage 2
(Figure 4B). At the end of the second stage, islet clusters
formed gradually. With continuous incubation, IPC clus-
ters increased in number and mass (Figure 4C and D).
IPC clusters were stained with DTZ by the end of the
last stage (Figure 4F). RNA was extracted from the IPC
Figure 2 UC-MSC phenotype analysis. MSCs derived from umbilical cord were detached with trypsin-EDTA and stained with fluorescence
antibodies against surface molecules indicated and analyzed by flow cytometry present in histogram plots. Appropriate isotype controls were
performed (for each antibody isotype) to assess cell auto-fluorescence and background staining. MSCs were positive for CD73 (99%), CD90 (99%),
CD105 (95%), CD166 (98%), negative for hematopoietic marker CD34 (1.7%), leukocyte common antigen CD45 (2.2%), HLA-DR (1.3%) and monocyte
marker CD14 (1.5%).
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expression level of insulin and insulin related genes, in-
cluding Pdx1, Ngn3 and Pax4. Pdx1 and insulin mRNA
levels of IPCs significantly increased than those in the
control group. When stimulated with a high concentra-
tion of glucose, the IPCs could secrete insulin, as deter-
mined by ELISA (Figure 5B). Collectively, IPCs were
successfully induced using a published method, but the
insulin secretion was low. Next, we determined whether
adding extracellular matrix recombination human lam-
inin 411 would increase the yield of IPCs.Figure 3 Evaluation of UC-MSC pluripotency. (A) P4 UC-MSCs were ind
After 21 days of adipogenesis differentiation, adipocytes were stained by o
were stained with Alizarin red. (C) At the end of chondrogenesis differentia
are shown at 100 ×magnification.Laminin 411 increased Ngn3 and Pdx1 expression
UC-MSCs were cultured in the differentiation media
with and without exposure to laminin 411 for IPC gen-
eration and maturation. Our result showed that culture
system with laminin 411 yielded more clusters than the
one without laminin 411 (24.3 ± 1.0 v.s 14.7 ± 1.8 clus-
ters/well). Moreover, as shown in Figure 4E, the clusters
of IPC generated in the system with laminin 411 con-
tained more cells than the one without laminin 411. At
the end of the 4 stage culture, total RNA were extracted,
and insulin related genes were assessed using qPCR. IPCsuced with differentiation kits according to manufacturer’s instructions.
il red O. (B) After 21 days of osteogenesis differentiation, osteocytes
tion, chondrocyte mass was stained with Alcian blue. Representatives
Figure 4 IPC differentiation. (A) UC-MSCs culture before IPCs differentiation induction. (B) UC-MSCs aggregated together during the differenti-
ation stage 2. (C) Insulin clusters were formed at late stage 2. (D) IPC clusters at the end of the last stage. (E) Adding laminin 411 group formed
the IPC clusters. (F) DTZ stained the IPCs cluster. Representatives are shown at 100 ×magnification.
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showed significantly higher Pdx1 mRNA expression than
the one without laminin 411 (IPC) (P < 0.05, Figure 6A).
Consistently, Pdx1 protein level was significantly up-
regulated by laminin 411, as determined by immuno-
fluorescence staining (Figure 6B) and Western blot ana-
lysis (Figure 6C). The Ngn3 mRNA expression level of
the IPCs + 411 was numerically higher than that of the
IPCs, but the difference between these two groups did
not reach significance (P > 0.05). Nevertheless, the protein
expression level of Ngn3 of the IPCs + 411 was signifi-
cantly higher than that of the IPCs (P < 0.05, Figure 6C).
There were no significant difference in the expression
of other insulin related genes, Pax4, Pax6 and Glucagon,
at mRNA and protein levels between IPC + 411 and IPC
(data not shown).Laminin 411 augmented insulin expression and secretion
IPC + 411 showed significantly higher insulin mRNA
expression than IPC (Figure 5A). After stimulation with
a high concentration of glucose for insulin release, the
insulin concentration in the supernatants of IPC + 411
was approx. 4 fold higher than that of IPC (612.1 ± 40.78
μIU/ml v.s 189.8 ± 93.05 μIU/ml, P < 0.05) (Figure 5B).
Insulin expression in the IPC clusters of the two groups
was further confirmed by immunofluorescence staining
of insulin (Figure 5B).Laminin 411 induced differentiation of MSC into
pancreatic precursor
Li et al. reported that adipose-derived MSC (AD-MSC)
could be induced into IPCs through a pancreatic precur-
sor formation pathway [19]. It was further confirmed in
an Embryonic Stem Cells (ESCs) differentiation protocol
[20]. So we want to know whether laminin 411 was
through the same pathway to induce IPC generation. To
this end, the cells were harvested from the end of the
second stage of differentiation to compare the expres-
sion of Foxa2 and Sox17, markers for pancreatic precur-
sor cells [21]. As expected, Foxa2 and Sox17 mRNA
expression level of the cells exposed to laminin 411 was
significantly higher than that of the ones without expos-
ure to laminin 411 (P < 0.05, Figure 7A, 7B), suggesting
a role of laminin 411 in the induction of pancreatic pre-
cursor differentiation from MSCs.Positive correlation between insulin secretion and insulin
related genes
Having analyzed the correlation between insulin secre-
tion and insulin related gene expressions, we found
that the insulin secretion level was positively corre-
lated with Pdx1 and Foxa2 gene expression, respect-
ively (P < 0.05 by Spearman’s correlation, Figure 7C,
7D), but not with Sox17 (P > 0.05 by Spearman’s cor-
relation, Figure 7E).
Figure 5 RNA and protein level of insulin in IPCs. (A) After glucose stimuli IPCs with or without laminin 411 group mRNA level of insulin was
determined using RT-PCR and expressed relative to an undifferentiated control and normalized to GAPDH. (B) Insulin release assay. At the end of
the 4 stage culture of IPCs, high concentration of glucose was added. Supernatant was collected and tested by ELISA. (C) Immunofluorescence
staining of insulin of IPCs with or without laminin 411. After culturing them for 4 stages, IPCs with or without laminin 411 were incubated with
anti-human insulin antibody. Nuclei were stained blue with DAPI. Each bar is the mean ± SEM (n = 3), *P < 0.05.
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glucose, improved survival and reduced HbA1c level in a
T1DM animal model
To evaluate the therapeutic effect of the IPCs, T1DM
animal models were generated as described in the mate-
rials and methods. FBG was monitored to assess glycaemia
(Figure 8A). On the 3rd day of cell transfusion, FBG level
was significantly lower than IPC and MSC groups,
respectively (P < 0.05, IPC + 411 vs IPC, Figure 8B). No
significant difference in FBG levels between IPC and
MSC groups vs control, respectively, was found (IPC vs
control; MSC vs control, data not shown). However,
the FBG level increased 2.5 weeks after cell infusion.
Afterwards, the FBG level of all groups reached up to
33.3 mmol/L, which was beyond the detectable range of
the glucose trips. We also observed that diabetes symp-
toms such as polyuria and polydipsia of T1DM rats were
more effectively ameliorated by IPC + 411 transfusion than
by IPC or MSC. In addition, the weights of the rats that
received IPC + 411, IPC or MSC transfusion were slightly
increased compared with controls (Figure 8C). Both IPC
+ 411 and IPC transfusion groups showed elongated sur-
vival time than MSC group (Figure 8D). IVGTT test wasdone at day 50 of the animal experiment, but no signifi-
cant differences in GTT between IPC + 411 and IPC were
observed, indicating that transfused IPC did not correct
intrinsic β cell activity and treatment efficacy was primar-
ily attributable to insulin secreted by the IPCs. Up to
70 days of the cell transfusion, the survival rate in IPC +
411 and IPC group was 100%, while MSC group 75% and
the control group 0%.
Our results demonstrated that the HbA1c concen-
tration in the blood of the rats treated by IPC + 411 was
significantly decreased when compared with that of
control, IPC and MSC groups, respectively, as shown in
Figure 8E (P < 0.01, IPC + 411 vs control; P < 0.05, IPC
+ 411 vs IPC; IPC + 411 vs MSC; P < 0.05, respectively).
(In these comparisons made, newly generated T1DM
models from the same rat strain by following the same
protocol were applied as controls). Meanwhile, the dif-
ference in HbA1c concentration between IPC and con-
trol, and MSC and control groups reached significance,
respectively (P < 0.05, IPC vs control; P < 0.05, MSC vs
control). These results suggested that therapeutic effect
of IPC + 411 on T1DM was much more efficient than
IPC and MSC.
Figure 6 RNA and protein levels of insulin-related genes in IPCs. (A) After glucose stimuli IPCs with or without laminin 411 group mRNA level
of Pdx1 was determined using RT-PCR and expressed relative to an undifferentiated control and normalized to GAPDH. (B) Immunofluorescence
staining of Pdx1 in IPCs with or without laminin 411. After culturing them for 4 stages, IPCs with or without laminin 411 were incubated with
anti-human Pdx1 antibody. Nuclei were stained blue with DAPI. Quantitative analysis of mean fluorescence density of Pdx1 staining was shown
on the left. (C) Western blot analysis. Protein level of Ngn3 and Pdx1 of IPCs with or without laminin 411. Each bar is the mean ± SEM (n = 3), *P < 0.05.
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In this study, we reported a laminin 411-containing
protocol to induce UC-MSC into IPCs. Based on our
present findings, combined with published studies, we
believe that the protocol reported here has the following
advantages: First, the IPC generation is free from gene
manipulation, which guarantees safety in the future
clinical application. Second, laminin 411 more effect-
ively increases the yield of IPCs and insulin secretion.
Third, the administration of laminin 411-exposed IPCs
significantly attenuates FBG, HbA1c and improves the
survival in DM rats, which demonstrates their thera-
peutic efficacy in vivo.
IPCs was first described to be generated from mouse
ESCs [18]. Thereafter, generation of IPCs from human
neural progenitor cell [22], ESCs [23], liver cells [24,25],
pancreatic non-endocrine cells [26], placenta-derived
multipotent stem cells [27], gene modified BM-MSC [5],and pancreatic cells [28] have been reported. With re-
spect to efficiency of IPC differentiation and maturation,
protocols used in the previous studies have certain
disadvantages. First, the induction duration of IPCs is
always longer than 21 days or even more than 2 months.
Second, only about 20% of these IPCs could secrete
insulin [22]. Third, insulin release of IPCs was still insuf-
ficiency in vitro [29]. As shown in the present study,
using our laminin 411-containing protocol, only about
2 weeks were required for IPC generation from UC-
MSCs and up to 612.1 ± 40.78 μIU/ml insulin release
in vitro.
MSCs appear to be promising stem cells applied in clin-
ical setting. MSCs were first described in BM (BM-MSC).
However, there is age-related differences in the differen-
tiation capacity of BM-MSCs and AD-MSCs [30-32],
donor age and long term passages also affect the cha-
racteristic of BM-MSC [33]. To apply UC-MSCs have
Figure 7 Definitive endoderm (DE) marker Sox17 and Foxa2 expression level and correlation analysis. (A) IPCs with or without laminin
411 group mRNA level of Foxa2 was determined using RT-PCR and expressed relative to an undifferentiated control and normalized to GAPDH.
(B) mRNA level of Sox17 in IPCs with or without laminin 411 was determined using RT-PCR and expressed relative to an undifferentiated control
and normalized to GAPDH. (C) Correlation of insulin secretion with Foxa2 gene expression (r = 0.9531, n = 3, P < 0.05). (D) Correlation of insulin
secretion with Sox17 gene expression (r = 0.7989, n = 3, P > 0.05). (E) Correlation of insulin secretion with Pdx1 gene expression (r = 0.8890, n = 3,
P < 0.05). Bars: mean ± SEM (n = 3), and *P < 0.05.
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to obtain without invasion and are medical wastes during a
natural delivery. Secondly, UC-MSCs have less ethical prob-
lems than ESCs. Thirdly, UC-MSCs could be large-scale ex-
pansion in vitro under GMP condition. Moreover, evidence
shows that proliferation ability and pluripotency markers of
UC-MSCs are better than those derived from BM [34].
Laminin 411 was one kind of extracellular matrix (ECM)
protein. ECM contains fibronectin, laminin, and collagens,
which can profoundly influence stem cell fate choices [35].
Laminin was found to support mouse ESCs proliferation
in vitro [36] and soluble laminin could increase insulin
secretion by 20% in murine islets in vitro [37]. In islet
transplantation, treating islets with laminin prior to trans-
plantation will help to maintain insulin production untilnew capillaries are formed in transplanted islets. Murine
insulinoma cell line MINI6 cultured in laminin 411 could
increase the insulin gene expression significantly [38]. Lin
observed that fibronectin and laminin could induce the
hTERT-over-expression BM-MSC into IPCs [11]. However,
the type of laminin used in their study was unclear. Our
findings clearly demonstrated that laminin 411 was the one
capable of inducing maturation and differentiation of IPCs.
Flanagan reported that laminin 411 might be the ligand for
MCAM (CD146) and CD29 [39]. CD146 and CD29 are
shown to be expressed in MSCs [40-44]. Ligation of the re-
ceptor(s) with laminin 411 on MSCs may regulate IPC dif-
ferentiation and maturation.
Our results revealed that laminin 411 could induce
Pdx1 and Ngn3 expression both at mRNA and protein
Figure 8 Blood glucose level, weight and survival analysis of STZ induced T1DM rats. (A) Fasting blood glucose levels were monitored
twice a week as indicated in samples obtained from the tail vein using Blood Glucose Test Strips (Roche Diagnostics, Basel, Switzerland). Blood
glucose over 33.3 mmol/L was beyond the measuring scale. (B) Fasting blood glucose level 3 days after IPCs with laminin 411 infusion, Bars:
mean ± SEM (n = 3), and *P < 0.05. (C) Weights were monitored twice a week as indicated. (D) Survival curve of animal tests. (E) HbA1c level at
the endpoint of the experiments. Bars: mean ± SEM (n = 4), and *P < 0.05, **P < 0.01.
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creases the maturation of IPCs. Pdx1 also known as IPF-
1, is the master regulator of the pancreatic development,
and plays a crucial role during the development and
function of pancreatic β-cells [45]. Mice and humans
lacking Pdx1 are apancreatic in the embryonic develop-
ment [46]. Pdx1 transfected into human BM-MSC could
induce IPCs and injected to diabetes mice could sustain
a decline of blood glucose more than 80 d [9]. During
the ontogeny of pancreatic β-cells, pancreatic progenitor
cells that express Ngn3 would develop into endocrine
cells. In those cells, only Pdx1+ Ngn3+ progenitor cells
could develop into insulin-producing β-cells [47].
Mature pancreatic β-cells are also Pdx1 positive. Our
current protocols of IPCs differentiation markedly in-
duced Pdx1+ expression, indicating that laminin 411
may play essential roles in regulation of the yield of
IPCs. Moreover, the presence of laminin 411 could
markedly increase the IPC cluster number and size. Of
note, the laminin 411 exposed-cells harvested in the
middle producer of IPC induction were also shown toexpress high level of Pdx1, indicating that laminin 411
may induce MSC differentiation into pancreatic pro-
genitor cells (intermediate insulin producing cells) first
prior to IPC formation.
Definitive Endoderm (DE) is defined as a population
of squamous cells that expressed Foxa2, Sox17 and
CXCR4, which is formed after the prior formation of
primitive endoderm [48]. Only DE can be further differ-
entiated into specific endoderm lineages [21]. Therefore,
we determined whether laminin 411 could regulate the
expression of DE. Our results showed that laminin 411
markedly increased the expression of Sox17 and Foxa2.
Furthermore, insulin secretion level was positively cor-
related with Foxa2 and Pdx1 expression. Therefore, our
results demonstrate that laminin 411-induced differen-
tiations of MSCs into IPC may be through the DE
pathway.
In the cell transfusion experiments with DM rats,
IPC + 411 group decreased the FBG level significantly
at the 3rd day after transfusion, and much earlier than
IPC and MSC groups. Afterwards, FBG level of the rats
Qu et al. Journal of Translational Medicine 2014, 12:135 Page 11 of 12
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reached to 33.3 mmol/L after two and half weeks. Of
note, 33.3 mmol/L (600 mg/dL) is the highest level that
could be measured by the technique glucose trips applied
in current study. Due to such technical limitation, we did
not know exact glucose levels of rats between different
groups after the cell transfusions beyond two and half
weeks. Nevertheless, we found that rats treated with IPC
+ 411 presented less DM symptoms than the IPC group,
indicating a better blood glucose control by IPC + 411
than IPC. In line with this speculation, our results of
HbA1c analysis demonstrated that at the end of the
experiment (on day 70 after the cell transplantation) the
HbA1c level in IPC + 411 treatment group was signifi-
cantly lower than control and other cell transfusion
groups. Considering the facts that HbA1c was a maker
reflecting the average blood glucose level over the previous
2 to 3 months and higher level of HbA1c indicates poorer
control of blood glucose levels, our findings above suggest
a long term therapeutic or blood glucose control effect of
IPC + 411 on T1DM. We also observed that IPC + 411
showed more superior long-term therapeutic effects over
the IPC without exposure to laminin 411 and MSC in
terms of survival and disease symptom control.
Conclusion
Our laminin 411 containing IPC induction protocol sig-
nificantly enhanced differentiation efficiency of IPCs from
MSCs derived from human cord tissues. Moreover, trans-
fusion of the IPCs generated from laminin 411 protocol
resulted in a long-term therapeutic effects on T1DM. Our
findings here highlight a crucial role of laminin 411 in the
induction of IPCs differentiation from human MSC and a
potential clinical application of the IPCs + 411 in the treat-
ment of T1DM as well as type 2 DM in the future.
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